This presentation provides a clinical update on minimally invasive approaches to esthetic implant site development. The use of recombinantly engineered platelet-derived growth factor-BB (rhPDGF-BB) has accelerated a broader shift toward less invasive surgical procedures for bone and soft tissue augmentation, offering an alternative to more traditional grafting techniques in appropriately selected cases.

The discussion covers indications for biologic-assisted grafting, treatment planning considerations for the esthetic zone, and how minimally invasive site development techniques can support predictable esthetic and functional outcomes in implant therapy.

Dr. Marc Nevins is a periodontist on the faculty of Harvard School of Dental Medicine whose research has focused on bone and soft tissue regeneration around dental implants.